Core Viewpoint - The innovative intracranial injection method for oncolytic virus therapy enhances the convenience of treating brain tumors, demonstrating safety and efficacy in treating pediatric diffuse intrinsic pontine glioma (DIPG) with the new oncolytic virus Ad-TD-nsIL12 [1][6] Group 1: Oncolytic Virus Therapy - Oncolytic virus therapy is emerging as a disruptive new strategy for cancer treatment, with the potential to revolutionize clinical practices [2] - This therapy selectively infects and destroys tumor cells while activating the immune system, providing a dual mechanism of action against tumors [3][4] - The engineered oncolytic virus is designed to replicate specifically within tumor cells, minimizing harm to normal cells and enhancing therapeutic efficacy [5] Group 2: Mechanism and Design - The oncolytic virus used in the study is based on human adenovirus type 5 (Ad5) and has undergone genetic modifications to improve targeting and reduce toxicity [5] - Key genetic deletions enhance the virus's ability to kill tumor cells and improve the presentation of tumor-specific antigens to the immune system [5] - The introduction of non-secretory interleukin-12 (IL-12) maintains normal levels in the bloodstream, promoting systemic anti-tumor immunity while avoiding side effects from elevated IL-12 levels [5] Group 3: Clinical Trials and Results - Clinical trials have confirmed the safety of the oncolytic virus Ad-TD-nsIL12, with significant preclinical and clinical evidence supporting its effectiveness [6] - Over 200 oncolytic virus-related clinical trials are currently underway globally, with a significant portion originating from China [7] - Notable results from CG Oncology's phase 3 trial showed complete tumor disappearance in 82 out of 110 patients treated with their oncolytic virus therapy [7] Group 4: Future Directions - To accelerate the clinical translation of oncolytic virus therapy, collaboration between basic and clinical research is essential, along with enhanced communication among researchers and clinicians [7] - Future studies will explore the combination of oncolytic virus therapy with surgery, radiotherapy, and antibody treatments to address the heterogeneity of malignant tumors [8]

Core Viewpoint - The innovative intracranial injection method for oncolytic virus therapy enhances the treatment of brain tumors, demonstrating safety and efficacy in treating pediatric diffuse intrinsic pontine glioma (DIPG) [1][6]. Group 1: Oncolytic Virus Therapy - Oncolytic virus therapy is emerging as a disruptive new strategy for cancer treatment, with the potential to revolutionize clinical approaches [2]. - This therapy utilizes engineered viruses that selectively infect and destroy tumor cells while activating the immune system, providing a dual mechanism of action [3][4]. - The modified oncolytic virus (Ad-TD-nsIL12) shows improved targeting of tumor cells and reduced toxicity to normal cells through specific genetic alterations [5][6]. Group 2: Clinical Trials and Efficacy - Recent clinical trials have confirmed the safety of the oncolytic virus Ad-TD-nsIL12, with significant preclinical and clinical evidence supporting its effectiveness [6]. - Global statistics indicate over 200 ongoing clinical trials related to oncolytic viruses, with a substantial portion originating from China, highlighting the rapid advancement in this field [7]. - A notable study demonstrated that a new oncolytic virus (VG161) significantly extended the median overall survival of patients with recurrent liver cancer from 9.4 months to 17.3 months [7]. Group 3: Future Directions - The focus for future research includes enhancing collaboration between basic and clinical research to facilitate the transition of oncolytic virus therapies into clinical practice [7]. - The team plans to explore combination therapies involving oncolytic viruses with surgery, chemotherapy, and antibody treatments to address the heterogeneity of malignant tumors [8].

Core Insights - Three companies from the Optics Valley talent program have submitted their listing applications to the Hong Kong Stock Exchange, indicating a growing interest in the biotechnology and technology sectors in the region [1][3]. Company Summaries - **Juxin Microelectronics**: Established in 2016, the company has evolved from pressure sensors to providing intelligent perception, machine vision, and imaging technology solutions. Its product line includes optical sensors, 3D dToF and iToF image sensors, and smart audio amplifiers, with applications in mobile smart devices, IoT, and emerging fields like robotics and automotive electronics [1][3]. - **AIMISON**: Founded in 2015, AIMISON focuses on early detection of high-incidence and high-mortality cancers. The company has developed a comprehensive product pipeline based on its proprietary methylation detection technology, covering major cancer types and expanding into various cancer detection products [3]. - **Binhui Biotechnology**: Established in 2010, Binhui is a leading global company in oncolytic virus therapy, dedicated to discovering, developing, and commercializing innovative cancer immunotherapies. The company has developed five products at different research stages based on its proprietary technology platforms [3]. Investment Background - The Optics Valley Talent Fund was established in 2015 to support talent enterprises through a model of "non-repayable funding + equity investment," having invested in 337 companies to date. In 2021, a 1 billion yuan investment guidance fund was set up to further support local projects, with a total investment amount of 552 million yuan across 37 projects [5].

Core Viewpoint - A new wave of pharmaceutical companies is applying for listings on the Hong Kong Stock Exchange (HKEX), with 11 companies submitting applications in a two-day period, indicating a significant uptick in market activity [1][3]. Group 1: Listing Activity - Approximately 25 pharmaceutical companies have submitted listing applications to HKEX since September, with a notable concentration of 11 applications on September 29-30 [3]. - Companies such as Sichuan Good Doctor Cloud Medical Technology Group and Annoroad Gene Technology are among those applying, with some indicating they are unprofitable biotech firms under the HKEX Chapter 18A rules [1][3]. - The trend of "A+H" dual listings is emerging, with several companies already listed on A-shares also seeking to list on HKEX, enhancing their financing capabilities [5][6]. Group 2: Market Drivers - The HKEX's 18A listing rules, introduced in 2018, have created a pathway for unprofitable biotech companies to go public, while the "Tech Company Fast Track" launched in 2025 further streamlines the listing process for tech firms [4]. - Increased demand for healthcare services due to population aging and accelerated regulatory approvals from domestic drug monitoring agencies are contributing to a favorable environment for pharmaceutical companies [4]. Group 3: Financial Performance - Many of the companies applying for listings are currently unprofitable, with significant losses reported. For instance, Meikang Aote and its subsidiary Blue Nancheng reported losses of approximately 195 million yuan and 112 million yuan, respectively, in recent financial periods [9][10]. - The trend of unprofitable companies seeking listings under the 18A rules highlights the role of HKEX as an "innovation incubator" for the biotech sector [10]. Group 4: Future Implications - The rise of "A+H" listings is expected to reshape the competitive landscape of the domestic biotech industry, potentially accelerating industry consolidation and enhancing the market position of well-capitalized firms [7]. - Increased capital influx is anticipated to boost the development of innovative drugs and technologies, thereby improving overall industry innovation efficiency [7].

Core Insights - Researchers at Columbia University and Rockefeller University have developed a method using bacteria as "Trojan horses" to bypass the immune system and deliver viruses directly to tumors, marking a significant advancement in cancer treatment [2][3] - This "Trojan horse" system combines the tumor-targeting capabilities of bacteria with the virus's ability to infect and destroy cancer cells, providing a new approach for safe and precise cancer therapy [2] - The technology has been validated in mouse experiments and represents the first example of engineered collaboration between bacteria and oncolytic viruses, laying the groundwork for multi-biological combination therapies [2] Summary by Sections - **Bacterial-Viral Collaboration**: The research team successfully utilized bacteria, specifically Salmonella, to deliver oncolytic viruses to solid tumors, overcoming the challenge posed by the immune system [3] - **Clinical Application Potential**: The latest advancements indicate a significant step towards clinical application, with ongoing tests on various tumor types and the exploration of combining this system with clinically safe bacterial strains [3] - **Oncolytic Virus Therapy**: Oncolytic virus therapy, which uses naturally occurring or genetically modified viruses to specifically target and destroy cancer cells, shows strong potential, particularly in brain tumors, but faces challenges from the body's immune defenses [2]

140美元的注射能否缩小恶性肿瘤、重新唤醒免疫系统，甚至延长晚期癌症患者的生命?据研究基因工 程"肿瘤消融"疗法的中国科学家称，这就是溶瘤病毒疗法的潜力。 科学家们表示，这些低成本、高影响力的病毒在临床试验中显示出希望。目前中国正在进行约60次临床 试验，它们可以改变癌症治疗。 对这些病毒的研究始于一个多世纪前，但最近涉及基因工程的发展增强了它们的潜力。 迄今为止，全球已批准了五种溶瘤病毒疗法，主要在美国和日本。但中国研究人员正在该领域取得快速 进展，并且可以提供一种创新且经济实惠的治疗方法。 鼓舞人心的成果 今年1 月，《细胞》期刊上显示了一名58 岁宫颈癌晚期女性的病例。这名女性接受了实验性溶瘤病毒疗 法(她是试验中的 20 名患者之一)，治疗后她的转移性肿瘤消失了，且存活了36个多月。 广西医科大学肿瘤靶向学国家重点实验室赵永祥教授领导的团队使用转基因病毒将癌细胞"伪装"成猪的 组织，这引发了肿瘤的"超急性排斥反应"(就像破坏不匹配器官移植的免疫反应一样)。这项小型试验发 现，90%的耐药性癌症(肝癌、卵巢癌和肺癌)患者在接受该病毒治疗后，肿瘤缩小或趋于稳定。 他们对40名肝癌患者的试验结果于3 月发表 ...